Novel Therapeutics that Harness the Gut-Brain Axis
Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.
We are a team of passionate and committed scientists, data-geeks, advocates, and entrepreneurs, inspired to be a catalyst for change in the standard of care through first-in-class, breakthrough therapeutics that target the Gut-Brain Axis. Our goal is to positively impact healing and improve the quality of life for patients with neurological diseases and their families.
Who We Are
How We Do It
Interactions between the bacteria in our gut and our body are just as important as our genetics, and can contribute to disease.
We investigate how changes in the gut microbiome influence key processes in the nervous system, immune system and brain.
Bloom’s proprietary discovery platform, IrisRx™, allows us to adopt a fundamentally different approach to developing medicines. By leveraging our growing understanding of the Gut-Brain Axis, we design and develop more holistic therapeutics that target novel biology, resulting in superior safety profiles, and fewer side effects compared to other drugs on the market.
Leaps by Bayer
Leaps by Bayer invests in paradigm-shifting advances in the life sciences – breakthroughs that could change the world for the better.
Apollo Health Ventures
At Bloom, we are seeking innovative, passionate, and motivated team players- committed to transforming the lives of individuals with rare and complex neurological diseases. We have built a team with extensive scientific, business, clinical and leadership backgrounds. Our ideas are developed into breakthrough science.